Josh Hamilton,

DNP, APRN-BC, CTMH, CNE, CLNC, FAANP

Josh Hamilton,

DNP, APRN-BC, CTMH, CNE, CLNC, FAANP

Josh Hamilton,

DNP, APRN-BC, CTMH, CNE, CLNC, FAANP
Chief Clinical Officer, The Hamilton Group Behavioral Health LLC; Clinical Professor and Chair, College of Nursing, Washington State University

Josh Hamilton, DNP, APRN-BC, CTMH, CNE, CLNC, FAANP, is in private practice in Las Vegas, where he serves patients via telebehavioral health in more than six states. With more than two decades of nursing experience, he also holds professorial appointments, leadership positions, and consults in higher education. Previously, he was associate medical director for the largest managed care behavioral health network in the desert Southwest. His professional interests include neurobiology, pharmacology, and epigenetics. He is an internationally recognized speaker on these and related topics at conferences and professional meetings. He served on the psychiatric medication working group at the Center of Excellence in Regulatory Science and Innovation, a FDA-sponsored project at the University of Maryland. He is a NEI Master Psychopharmacologist and a fellow of the American Association of Nurse Practitioners. Josh was America’s Top Psychiatric NP in 2021.

Josh's Shared Resources

Treatment-Resistant Schizophrenia: Challenges and Pathways Forward

Treatment-resistant schizophrenia (TRS) is defined by persistent positive symptoms despite trials with at least two different antipsychotics at adequate dose...
CURATED BY:
Josh Hamilton,
DNP, APRN-BC, CTMH,
CNE, CLNC, FAANP

Study Finds No Clear Advantage of CBT Over Other Therapies for Schizophrenia

Authors of this Cochrane Review assessed the effectiveness of cognitive behavioral therapy (CBT) compared to other psychosocial therapies when used...
CURATED BY:
Josh Hamilton,
DNP, APRN-BC, CTMH,
CNE, CLNC, FAANP

Researchers Investigate Relapse Risk and Predictors in Those With Schizophrenia Withdrawn From Treatment

This study quantified the risk and predictors of relapse among individuals with schizophrenia withdrawn from antipsychotic maintenance treatment....
CURATED BY:
Josh Hamilton,
DNP, APRN-BC, CTMH,
CNE, CLNC, FAANP

Long-Acting Injectable Antipsychotics for Schizophrenia and Bipolar I Disorder

Long-acting injectable antipsychotics (LAIs) are crucial for maintaining treatment in individuals with schizophrenia (SCZ) or bipolar I disorder (BP-I), the...
CURATED BY:
Josh Hamilton,
DNP, APRN-BC, CTMH,
CNE, CLNC, FAANP

Resilience Factors in Schizophrenia: Key Psychological Constructs That May Protect Against Suicide

Suicide is a significant concern for individuals with schizophrenia, but not all individuals with this diagnosis attempt or die by...
CURATED BY:
Josh Hamilton,
DNP, APRN-BC, CTMH,
CNE, CLNC, FAANP

Effective Interventions for Relapse Prevention in Schizophrenia

Authors of this systematic review and network meta-analysis aimed to assess the efficacy, acceptability, and tolerability of psychosocial and psychological...
CURATED BY:
Josh Hamilton,
DNP, APRN-BC, CTMH,
CNE, CLNC, FAANP
Share